|
Sage Therapeutics Inc (NASDAQ: SAGE) |
|
Sage Therapeutics Inc
SAGE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Sage Therapeutics Inc 's sales fell
by -83.56 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 4
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Sage Therapeutics Inc net loss increased from $-33 millions, to $-96 millions in IV. Quarter 2024,
• More on SAGE's Growth
|
|
Sage Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.26 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 11.23.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
• More on SAGE's Valuation
|
|
|
|
|
Sage Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.26 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 11.23.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
Sage Therapeutics Inc Price to Book Ratio is at 1 lower than Industry Avg. of 78.87. and higher than S&P 500 Avg. of 0.01
• More on SAGE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com